BidaskClub lowered shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) from a strong-buy rating to a buy rating in a report issued on Monday morning.
A number of other research analysts have also recently issued reports on the stock. Morgan Stanley upgraded shares of Alexion Pharmaceuticals from an equal weight rating to an overweight rating and lifted their price objective for the company from $101.08 to $138.00 in a report on Thursday, May 25th. Barclays PLC reiterated an overweight rating and set a $155.00 price objective on shares of Alexion Pharmaceuticals in a report on Tuesday, May 9th. Cowen and Company reiterated an outperform rating and set a $180.00 price objective on shares of Alexion Pharmaceuticals in a report on Friday, April 28th. J P Morgan Chase & Co cut shares of Alexion Pharmaceuticals from an overweight rating to a neutral rating in a report on Tuesday, May 23rd. Finally, Zacks Investment Research upgraded shares of Alexion Pharmaceuticals from a sell rating to a hold rating in a report on Tuesday, April 18th. Six analysts have rated the stock with a hold rating, twenty have given a buy rating and two have issued a strong buy rating to the stock. The stock presently has an average rating of Buy and an average price target of $156.13.
Shares of Alexion Pharmaceuticals (ALXN) opened at 134.63 on Monday. Alexion Pharmaceuticals has a 12 month low of $96.18 and a 12 month high of $145.41. The firm’s 50-day moving average is $130.54 and its 200 day moving average is $123.09. The company has a market capitalization of $30.05 billion, a PE ratio of 58.38 and a beta of 1.41.
Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.08 by $0.48. The firm had revenue of $912 million during the quarter, compared to analysts’ expectations of $846.15 million. Alexion Pharmaceuticals had a net margin of 15.31% and a return on equity of 12.47%. The business’s revenue was up 21.1% on a year-over-year basis. During the same period last year, the company earned $1.13 earnings per share. Equities research analysts predict that Alexion Pharmaceuticals will post $5.60 EPS for the current year.
In other Alexion Pharmaceuticals news, CEO Ludwig Hantson purchased 10,000 shares of the stock in a transaction dated Wednesday, June 14th. The shares were bought at an average price of $116.72 per share, with a total value of $1,167,200.00. Following the completion of the transaction, the chief executive officer now directly owns 38,725 shares in the company, valued at approximately $4,519,982. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Ann M. Veneman sold 700 shares of the business’s stock in a transaction that occurred on Monday, July 31st. The shares were sold at an average price of $137.74, for a total transaction of $96,418.00. Following the completion of the sale, the director now directly owns 6,315 shares in the company, valued at approximately $869,828.10. The disclosure for this sale can be found here. In the last three months, insiders bought 2,019,734 shares of company stock worth $235,606,846. Insiders own 4.35% of the company’s stock.
Several hedge funds have recently bought and sold shares of the stock. Morgan Stanley raised its stake in Alexion Pharmaceuticals by 112.0% in the first quarter. Morgan Stanley now owns 585,482 shares of the biopharmaceutical company’s stock valued at $70,983,000 after buying an additional 309,299 shares during the period. DekaBank Deutsche Girozentrale raised its stake in Alexion Pharmaceuticals by 18.2% in the first quarter. DekaBank Deutsche Girozentrale now owns 114,493 shares of the biopharmaceutical company’s stock valued at $14,017,000 after buying an additional 17,642 shares during the period. Sumitomo Mitsui Asset Management Company LTD raised its stake in Alexion Pharmaceuticals by 10.9% in the first quarter. Sumitomo Mitsui Asset Management Company LTD now owns 18,859 shares of the biopharmaceutical company’s stock valued at $2,286,000 after buying an additional 1,849 shares during the period. Baird Financial Group Inc. raised its stake in Alexion Pharmaceuticals by 219.0% in the first quarter. Baird Financial Group Inc. now owns 14,606 shares of the biopharmaceutical company’s stock valued at $1,771,000 after buying an additional 10,028 shares during the period. Finally, LS Investment Advisors LLC raised its stake in Alexion Pharmaceuticals by 13.0% in the first quarter. LS Investment Advisors LLC now owns 6,131 shares of the biopharmaceutical company’s stock valued at $743,000 after buying an additional 706 shares during the period. 90.74% of the stock is currently owned by institutional investors.
About Alexion Pharmaceuticals
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
What are top analysts saying about Alexion Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Alexion Pharmaceuticals Inc. and related companies.